ArticleBlood2020
An intact gut microbiome protects genetically predisposed mice against leukemia.
Article in Blood, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 101 citations in OpenAlex.
- Randomized Double-Blind Phase II Trial of Fecal Microbiota Transplantation Versus Placebo in Allogeneic Hematopoietic Cell Transplantation and AML.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Timing of microbial exposure and risk of infection-promoted acute lymphoblastic leukemia.Haematologica · 2026Article
- The gastrointestinal microbiome and constituent short-chain fatty acids: a narrative review of an underexplored axis in acute lymphoblastic leukemia.Gut pathogens · 2026Review
- The Role of Gut Microbiota in Acute Myeloid Leukemia.Journal of clinical medicine · 2026Review
- The Gut Microbiota in Hematologic Malignancies: Mechanisms, Clinical Associations, and Translational Opportunities.Nutrients · 2026Review
- Deletion of 9p drives B-ALL through heterozygous inactivation of Pax5 and Cd72 in preleukemic cells.JCI insight · 2026Article
- Lactobacillus reuteri SKLAN202402ZF inhibited by early-life lincomycin exposure alleviate intestinal damage and inflammation sensitivity.Microbiome · 2026Article
- The impact of gut microbiota on leukemia and prospects for novel therapies.Infectious medicine · 2026Review
- The Gastro-Intestinal Microbiota in Haematology.Acta haematologica · 2026Review
- Pediatric leukemia: origins, pathogenesis, the role of microenvironment and immunological modulation.Frontiers in immunology · 2026Review
- PD-1 Expression Promotes Immune Evasion in B-ALL.Hematology reports · 2025Article
- The microbiome-cancer axis as a hidden contributor to early-onset tumorigenesis.Medical oncology (Northwood, London, England) · 2025Review
- IGH::IL3-Rearranged B-Cell Precursor Acute Lymphoblastic Leukemia With Hypereosinophilia in a Child With a Novel PAX5 Germline Variant.Genes, chromosomes & cancer · 2025Article
- Trajectories from single-cells to PAX5-driven leukemia reveal PAX5-MYC interplay in vivo.Leukemia · 2025Article
- Unlocking the Microbial Symphony: The Interplay of Human Microbiota in Cancer Immunotherapy Response.Cancers · 2025Review
- Microbiome Modulation in Pediatric Leukemia: Impact on Graft-Versus-Host Disease and Treatment Outcomes: A Narrative Review.Children (Basel, Switzerland) · 2025Review
- Advancing therapeutic strategies for graft-versus-host disease by targeting gut microbiome dynamics in allogeneic hematopoietic stem cell transplantation: current evidence and future directions.Molecular medicine (Cambridge, Mass.) · 2025Review
- Interplay between host genetics and gut microbiome composition in the Japanese population.Frontiers in microbiomes · 2025Article
- Unraveling the Role of the Microbiota in Cancer Immunotherapy: A New Frontier.Research (Washington, D.C.) · 2025Review
- TEMPTED: time-informed dimensionality reduction for longitudinal microbiome studies.Genome biology · 2024Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
23 authors at 9 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The majority of childhood leukemias are precursor B-cell acute lymphoblastic leukemias (pB-ALLs) caused by a combination of prenatal genetic predispositions and oncogenic events occurring after birth. Although genetic predispositions are frequent in children (>1% to 5%), fewer than 1% of genetically predisposed carriers will develop pB-ALL. Although infectious stimuli are believed to play a major role in leukemogenesis, the critical determinants are not well defined. Here, by using murine models of pB-ALL, we show that microbiome disturbances incurred by antibiotic treatment early in life were sufficient to induce leukemia in genetically predisposed mice, even in the absence of infectious stimuli and independent of T cells. By using V4 and full-length 16S ribosomal RNA sequencing of a series of fecal samples, we found that genetic predisposition to pB-ALL (Pax5 heterozygosity or ETV6-RUNX1 fusion) shaped a distinct gut microbiome. Machine learning accurately (96.8%) predicted genetic predisposition using 40 of 3983 amplicon sequence variants as proxies for bacterial species. Transplantation of either wild-type (WT) or Pax5+/- hematopoietic bone marrow cells into WT recipient mice revealed that the microbiome is shaped and determined in a donor genotype-specific manner. Gas chromatography-mass spectrometry (GC-MS) analyses of sera from WT and Pax5+/- mice demonstrated the presence of a genotype-specific distinct metabolomic profile. Taken together, our data indicate that it is a lack of commensal microbiota rather than the presence of specific bacteria that promotes leukemia in genetically predisposed mice. Future large-scale longitudinal studies are required to determine whether targeted microbiome modification in children predisposed to pB-ALL could become a successful prevention strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.